Verstraete M, Hess H, Mahler F, Mietaschk A, Roth F J, Schneider E, Baert A L, Verhaeghe R
University Hospital Gasthuisberg, University of Leuven, Belgium.
Eur J Vasc Surg. 1988 Jun;2(3):155-9. doi: 10.1016/s0950-821x(88)80068-9.
Recombinant tissue-type plasminogen activator (rt-PA) was infused at a rate of 10 mg/h into 50 thrombosed femoral and popliteal arteries. Patency was restored in 43 but a secondary angioplasty led to 2 reocclusions and in 3 patients early rethrombosis occurred. A favourable clinical result was thus obtained in 38 patients (76%). Thirteen bleeding complications occurred in 10 patients, mainly haematomas at puncture sites. One patient required blood transfusion for gastro-intestinal bleeding from a previously unknown ulcer. The angiographic recanalisation rate in 16 patients who received a slower infusion of rt-PA (5 or 3 mg/h) was 94% and the clinical success rate in this series was 81%. However, the incidence of bleeding complications was not decreased by the slower infusion rate. The data obtained confirm the feasibility of rt-PA thrombolysis in peripheral arterial thrombosis and warrant a comparative study with streptokinase.
以10毫克/小时的速率将重组组织型纤溶酶原激活剂（rt-PA）注入50条发生血栓形成的股动脉和腘动脉。43条血管恢复通畅，但二次血管成形术导致2条血管再次闭塞，3例患者发生早期再血栓形成。因此，38例患者（76%）获得了良好的临床结果。10例患者出现了13例出血并发症，主要是穿刺部位的血肿。1例患者因先前未知的溃疡导致胃肠道出血而需要输血。16例接受较慢速率rt-PA输注（5或3毫克/小时）的患者的血管造影再通率为94%，该系列的临床成功率为81%。然而，较慢的输注速率并未降低出血并发症的发生率。所获得的数据证实了rt-PA溶栓治疗外周动脉血栓形成的可行性，并值得与链激酶进行对比研究。
